Takeda Pharmaceutical's Liabilities and Shareholders Equity rose 74.34% to $100.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $388.5 billion, marking a year-over-year decrease of 366.21%. This contributed to the annual value of $93.5 billion for FY2025, which is 1071.72% down from last year.
According to the latest figures from Q4 2025, Takeda Pharmaceutical's Liabilities and Shareholders Equity is $100.1 billion, which was up 74.34% from $98.2 billion recorded in Q3 2025.
Takeda Pharmaceutical's 5-year Liabilities and Shareholders Equity high stood at $122.0 billion for Q1 2021, and its period low was $93.4 billion during Q1 2025.
Over the past 5 years, Takeda Pharmaceutical's median Liabilities and Shareholders Equity value was $103.6 billion (recorded in 2023), while the average stood at $104.6 billion.
As far as peak fluctuations go, Takeda Pharmaceutical's Liabilities and Shareholders Equity surged by 359.58% in 2021, and later plummeted by 1443.13% in 2022.
Quarter analysis of 5 years shows Takeda Pharmaceutical's Liabilities and Shareholders Equity stood at $111.7 billion in 2021, then dropped by 14.43% to $95.6 billion in 2022, then increased by 0.66% to $96.2 billion in 2023, then grew by 3.27% to $99.4 billion in 2024, then increased by 0.74% to $100.1 billion in 2025.
Its Liabilities and Shareholders Equity was $100.1 billion in Q4 2025, compared to $98.2 billion in Q3 2025 and $96.8 billion in Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value